
|Articles|May 5, 2005
Tamoxifen shown to reduce gynecomastia in PCa patients
Tamoxifen (Nolvadex) reduces the frequency of gynecomastia and breast pain in prostate cancer patients taking bicalutamide (Casodex), according to a study in Lancet Oncology (2005; 6:295-300).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests potential diuretic effect with nadofaragene firadenovec
2
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
3
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











